Meta-Analysis: The Effect of Statins on Albuminuria

  1. Kevin Douglas, MD;
  2. Patrick G. O'Malley, MD, MPH; and
  3. Jeffrey L. Jackson, MD, MPH
  1. From Walter Reed Army Medical Center, Washington, DC, and Uniformed Services University of the Health Sciences, Bethesda, Maryland.
    1. Figure 1. RCT = randomized, controlled trial.
      View larger version:
        Figure 1. RCT = randomized, controlled trial. Study flow diagram.
      • Figure 2. Residual statistical heterogeneity: I   = 23% (   = 0.27) for excretion < 30 mg/d; I   = 0% (   = 0.64) for excretion of 30 to 299 mg/d; and I   = 63% (   = 0.020) for excretion ≥ 300 mg/d. WMD = weighted mean difference in the proportional change from baseline to follow-up albuminuria (or proteinuria) between statin and placebo groups.
        View larger version:
          Figure 2. Residual statistical heterogeneity: I   = 23% (   = 0.27) for excretion < 30 mg/d; I   = 0% (   = 0.64) for excretion of 30 to 299 mg/d; and I   = 63% (   = 0.020) for excretion ≥ 300 mg/d. WMD = weighted mean difference in the proportional change from baseline to follow-up albuminuria (or proteinuria) between statin and placebo groups. Individual and pooled results of 15 randomized, placebo-controlled trials examining the effect of statins on albuminuria or proteinuria, stratified by baseline excretion.2P2P2P

        Responses to this article

        « Previous | Next Article »Table of Contents